{"component": "definition", "props": {"groups": [{"samples": [{"hash": "fyfL9QCOHq4", "uri": "/contracts/fyfL9QCOHq4#celgene", "label": "Contingent Value Rights Agreement (Bristol Myers Squibb Co)", "score": 31.1464750171, "published": true}, {"hash": "ktzR01KuOdc", "uri": "/contracts/ktzR01KuOdc#celgene", "label": "Contingent Value Rights Agreement (Bristol Myers Squibb Co)", "score": 30.8836413415, "published": true}, {"hash": "8ihCO5UxBfq", "uri": "/contracts/8ihCO5UxBfq#celgene", "label": "Contingent Value Rights Agreement (Bristol Myers Squibb Co)", "score": 30.87816564, "published": true}], "snippet": "shall have the meaning set forth in the Recitals of this CVR Agreement.", "size": 4, "snippet_links": [{"key": "the-recitals", "type": "clause", "offset": [36, 48]}, {"key": "cvr-agreement", "type": "clause", "offset": [57, 70]}], "hash": "e33124b49e76cb6b90b412e26bf17049", "id": 1}, {"samples": [{"hash": "ffLeXVRwfmC", "uri": "/contracts/ffLeXVRwfmC#celgene", "label": "Contingent Value Rights Agreement (OncoMed Pharmaceuticals Inc)", "score": 30.1991786448, "published": true}, {"hash": "9TUrhF6Blei", "uri": "/contracts/9TUrhF6Blei#celgene", "label": "Contingent Value Rights Agreement (OncoMed Pharmaceuticals Inc)", "score": 29.9281314168, "published": true}, {"hash": "8jg1IOfFEz1", "uri": "http://www.oncomed.com/SEC-Documents/0001193125-18-342951.pdf", "label": "www.oncomed.com", "score": 10.1704312115, "published": false}], "snippet": "means Celgene Co. and Celgene Corp., and each of their respective successors or assignees.", "size": 4, "snippet_links": [{"key": "celgene-corp", "type": "clause", "offset": [22, 34]}], "hash": "4f48d9c04832ec9bb3c976bf66a1f2ec", "id": 2}, {"samples": [{"hash": "jcWNjO2uzAB", "uri": "/contracts/jcWNjO2uzAB#celgene", "label": "License Agreement (Aadi Bioscience, Inc.)", "score": 32.8576317591, "published": true}, {"hash": "4f6rKux5wGy", "uri": "/contracts/4f6rKux5wGy#celgene", "label": "Investors\u2019 Rights Agreement (Sutro Biopharma Inc)", "score": 29.6570841889, "published": true}], "snippet": "means Celgene Corporation, a Delaware corporation.", "size": 4, "snippet_links": [{"key": "delaware-corporation", "type": "clause", "offset": [29, 49]}], "hash": "ba9971ad7720970891e3aa1ad0bbb3d5", "id": 3}, {"samples": [{"hash": "llpdvaB4Q6J", "uri": "https://www.ftc.gov/system/files/documents/cases/191_0061_c4690_bms_celgene_decision_and_order.pdf", "label": "www.ftc.gov", "score": 10.015742642, "published": false}, {"hash": "bjln5fuLcBU", "uri": "https://www.ftc.gov/system/files/documents/cases/decision_pages_from_bms-celgene_package_-3.pdf", "label": "www.ftc.gov", "score": 9.9349760438, "published": false}, {"hash": "4yOgfKmCf3k", "uri": "https://www.ftc.gov/system/files/documents/cases/bms-o2mapdf.pdf", "label": "www.ftc.gov", "score": 9.9349760438, "published": false}], "snippet": "means Celgene Corporation, its directors, officers, employees, agents, representatives, successors, and assigns; and the joint ventures, subsidiaries, partnerships, divisions, groups, and affiliates, in each case controlled by Celgene Corporation, and the respective directors, officers, general partners, employees, agents, representatives, successors, and assigns of each.", "size": 3, "snippet_links": [{"key": "joint-ventures", "type": "definition", "offset": [121, 135]}, {"key": "each-case", "type": "definition", "offset": [203, 212]}, {"key": "by-celgene", "type": "clause", "offset": [224, 234]}, {"key": "general-partners", "type": "definition", "offset": [288, 304]}], "hash": "7bf50afe1d302423b89e328744967854", "id": 4}, {"samples": [{"hash": "46zskL7aUsL", "uri": "https://www.sec.gov/Archives/edgar/data/14272/000114036119009278/nc10001974x1_ex4-1.htm", "label": "Supplemental Indenture (Bristol Myers Squibb Co)", "score": 18.3689253936, "published": false}, {"hash": "eXd9PJIl4dX", "uri": "https://www.kgibank.com/cosmos/T06/docs/BD201.pdf", "label": "Supplemental Indenture", "score": 13.6844626968, "published": false}, {"hash": "c2F7cA0NInm", "uri": "http://d18rn0p25nwr6d.cloudfront.net/CIK-0000014272/3f671a0f-e3e9-4c78-a5f9-91e4cd8d76cb.pdf", "label": "d18rn0p25nwr6d.cloudfront.net", "score": 10.5852156057, "published": false}], "snippet": "means Celgene Corporation, a Delaware corporation.\u201d", "size": 3, "snippet_links": [{"key": "delaware-corporation", "type": "clause", "offset": [29, 49]}], "hash": "c0b7a1498eab3a25b736e1d62b75f16c", "id": 5}, {"samples": [{"hash": "4kfmTpyOpdZ", "uri": "/contracts/4kfmTpyOpdZ#celgene", "label": "Contingent Value Rights Agreement (GX Acquisition Corp.)", "score": 32.2388774812, "published": true}], "snippet": "has the meaning set forth in the Recitals.", "size": 2, "snippet_links": [{"key": "the-recitals", "type": "clause", "offset": [29, 41]}], "hash": "8147307746bce1e7e7ce0d9d9441a89a", "id": 6}, {"samples": [{"hash": "jIZZwpfBRdD", "uri": "https://www.sec.gov/Archives/edgar/data/816284/000144530514000438/a20131231ex-1019.htm", "label": "Incentive Plan (Celgene Corp /De/)", "score": 13.1177275838, "published": false}], "snippet": "or \"the Company\" means Celgene Corporation and its successors.", "size": 2, "snippet_links": [{"key": "the-company", "type": "definition", "offset": [4, 15]}], "hash": "9510c4c87df67d454a7f3c3c8992837d", "id": 7}, {"samples": [{"hash": "ahpF7LSbN7C", "uri": "/contracts/ahpF7LSbN7C#celgene", "label": "License Agreement (Forma Therapeutics Holdings, Inc.,)", "score": 31.3436002738, "published": true}], "snippet": "has the meaning set forth in the Introductory Paragraph of the Agreement.", "size": 2, "snippet_links": [{"key": "introductory-paragraph", "type": "definition", "offset": [33, 55]}, {"key": "the-agreement", "type": "clause", "offset": [59, 72]}], "hash": "b51bf95e3529b6b51bcaaa514374eeca", "id": 8}, {"samples": [{"hash": "aD9LGmIj5Hb", "uri": "/contracts/aD9LGmIj5Hb#celgene", "label": "Master Development and License Agreement (Concert Pharmaceuticals, Inc.)", "score": 25.090349076, "published": true}], "snippet": "means either Celgene USA or CIS individually or both of them collectively, as the context dictates.", "size": 1, "snippet_links": [{"key": "the-context", "type": "clause", "offset": [78, 89]}], "hash": "d2532a9d5cf1ac07ed170b0798405b75", "id": 9}, {"samples": [{"hash": "2Y2ghIveISr", "uri": "/contracts/2Y2ghIveISr#celgene", "label": "License Agreement (Jounce Therapeutics, Inc.)", "score": 30.8480492813, "published": true}], "snippet": "has the meaning set forth in the Preamble.", "size": 1, "snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}], "hash": "8bc994fbf8747c57816edd3723d39ac7", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIQY2VsZ2VuZSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "shall have the meaning set forth in the Recitals of this CVR Agreement.", "title": "Celgene", "size": 30, "id": "celgene", "examples": ["<strong>Celgene</strong> may elect to self-insure all or parts of the limits described above.", "To the extent that any grant of a sublicense by <strong>Celgene</strong> or any Sublicensees under an Applicable New In-License triggers a payment obligation under such Applicable New In-License, Bluebird will pay same and <strong>Celgene</strong> will reimburse Bluebird for [***] of such payment within thirty (30) days of receipt of Bluebird\u2019s written invoice therefor.", "<strong>Celgene</strong> will provide Bluebird with copies of all applicable <strong>Celgene</strong> Licensed Product In-Licenses promptly following the effective date of the termination of this License Agreement.", "Such cooperation will include providing <strong>Celgene</strong> with reasonable access by teleconference or in-person at Bluebird\u2019s facilities to Bluebird personnel involved in the research and Development of Elected Candidate to provide <strong>Celgene</strong> with a reasonable level of technical assistance and consultation in connection with the transfer of such Know-How.", "<strong>Celgene</strong> (or its Sublicensee) will use its commercially reasonable efforts to minimize the amount of any of the foregoing payments owed to Third Parties.", "<strong>Celgene</strong> will responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices, any on-going clinical studies for which it has responsibility hereunder in which patient dosing has commenced or, if reasonably practicable and requested by Bluebird, allow <strong>Celgene</strong>, its Affiliates or its Sublicensees to complete such trials.", "Neither Bluebird nor any of its Affiliates has entered into any agreement or otherwise licensed, granted, assigned, transferred, conveyed or otherwise encumbered or disposed of any right, title or interest in or to any of its assets, including any intellectual property rights, that would in any way conflict with or impair the scope of any rights or licenses granted to <strong>Celgene</strong> hereunder.", "<strong>Celgene</strong> will be responsible for any costs associated with such wind-down.", "During such meeting, <strong>Celgene</strong> will disclose to Bluebird all material information regarding such Development.", "In addition to the foregoing, <strong>Celgene</strong> will provide Bluebird with such additional information regarding any such activities as Bluebird may reasonably request from time to time."], "related": [["gsk", "GSK", "GSK"], ["bms", "BMS", "BMS"], ["isis", "ISIS", "ISIS"], ["merck", "Merck", "Merck"], ["novartis", "Novartis", "Novartis"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}